Expression of PDL-1 IN Urothelial Carcinoma of the Bladder and Correlation with Clinicopathological Parameters in a Tertiary Care Centre in South India
Abstract: Background: Bladder Cancer is the ninth most common cancer worldwide. In India it ranks seventeenth among all malignancies. Urothelial carcinoma accounts for more than 90% of all bladder cancer cases. Introduction of immune checkpoint inhibitors targeting PD?1/PD?L1 has transformed the management of advanced cases of urothelial carcinoma. PD?L1 immunohistochemistry has emerged as a key biomarker to select patients and predict response to immune therapy Aim: To evaluate immunohistochemical expression of PD-L1 in Urothelial carcinoma of the bladder and assess its correlation with clinicopathological parameters. Materials and Methods: A hospital-based observational study was conducted on 55 confirmed Urothelial carcinoma cases. PDL-1 immunohistochemistry was performed on formalin-fixed paraffin-embedded sections. Associations were analyzed using Chi-square test. PDL-1 scoring was done by CPS (Combined Positive Score). CPS
Keywords: PD-L1, urothelial carcinoma, immunohistochemistry, muscle-invasive, tumour grade
How to Cite?: Dr. Madeeha Zeba, Dr. Kota Devender Reddy, Dr. Naval Kishore, "Expression of PDL-1 IN Urothelial Carcinoma of the Bladder and Correlation with Clinicopathological Parameters in a Tertiary Care Centre in South India", Volume 15 Issue 5, May 2026, International Journal of Science and Research (IJSR), Pages: 1510-1514, https://www.ijsr.net/getabstract.php?paperid=SR26306072722, DOI: https://dx.doi.org/10.21275/SR26306072722